Clinical trials: Normal Population
Aging, Obesity
Resistance Exercise Training in the Older Population With Obesity
Background: Aging leads to an alteration in the immune response, characterized by a chronic inflammatory state, and a progressive decrease in muscle quantity and quality, a situation that increases in women and in the presence of…
- Trial name
- RETOPO (NCT06367296)
- Testing
- Prolonged resistance exercise training
- Where
- 2 sites in Chile
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Universidad de La Frontera
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis who have not been previously treated with DMARDs.
- Trial name
- PALACE4 (NCT01307423)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 118 sites in United States, Australia and 16 more
- Volunteers
- 529 people
- Sponsor
- Amgen
Tuberous Sclerosis, Angiolipoma
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
This is an open label long term follow up study, open to those subjects who were previously enrolled in"RAD001 Therapy of Angiomyolipomata in Patients with Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis", CCHMC…
- Trial name
- NCT00792766
- Testing
- everolimus (RAD001)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
No Reflow Phenomenon, STEMI
No Reflow Phenomenon Incidence and Predictors
Background No reflow phenomenon is described in up to 65% of patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction (STEMI).
- Trial name
- NORM-PPCI (NCT04017169)
- Testing
- No intervention as observational study
- Where
- United Kingdom
- Volunteers
- 176 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Acne Vulgaris
Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face
To compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of Acne Vulgaris
- Trial name
- NCT03393494
- Testing
- Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product
- Where
- United States
- Volunteers
- 825 people
- Sponsor
- Padagis LLC
Breast Cancer
Strength After Breast Cancer
The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for…
- Trial name
- SABC (NCT06052488)
- Testing
- Strength After Breast Cancer
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- MGH Institute of Health Professions
Arthritis, Rheumatoid
A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.
This is an exploratory study to examine the effect of iNOS inhibition in rheumatoid arthritis patients. The study involves 28 days repeat dosing with GW274150 (dose determined by the results from a previous study), prednisolone…
- Trial name
- NCT00379990
- Testing
- GW274150, Prednisolone
- Where
- 2 sites in Serbia, United Kingdom
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Standard Versus High Dose Inactivated Influenza Vaccine in RA
Patients with rheumatoid arthritis have increased risk of seasonal influenza and influenza-related complications but have reduced vaccine immunogenicity.
- Trial name
- IV-RA (NCT02936180)
- Testing
- HD-TIV, SD-QIV
- Where
- Canada
- Volunteers
- 279 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Arthritis, Rheumatoid
A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JNJ-40346527 200 mg/day (100 mg twice daily) for 12 weeks, compared with placebo, in patients with active rheumatoid arthritis (RA) despite…
- Trial name
- NCT01597739
- Testing
- JNJ-40346527
- Where
- 32 sites in Argentina, Bulgaria and 8 more
- Volunteers
- 96 people
- Sponsor
- Janssen Research & Development, LLC
Myoma;Uterus
Safety & Efficacy of Non-Invasive Procedures Using Ultrasound-Guided HIFU 'Sonotrip V20' in Symptomatic Uterine Fibroids
This is a single-arm clinical trial evaluating the safety and efficacy of ultrasound-guided HIFU (Sonotrip V20) for symptomatic uterine fibroids. 57 cases will be enrolled at a Korean institution.
- Trial name
- NCT05972642
- Testing
- HIFU-treatment
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Systemic Lupus Erythematosus
Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood
To assess how the absolute bioavailability, dose proportionality, pharmacokinetics, safety and tolerability of epratuzumab compared when given as a subcutaneous (sc) injection as to when given as an intravenous (iv) infusion in…
- Trial name
- NCT02306629
- Testing
- Epratuzumab sc, Epratuzumab iv
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Breast Cancer, Emotional Disturbances
Improving Emotion Regulation at the End of Breast Cancer Treatment
The end of treatment marks the beginning of a challenging period for breast cancer patients. While this period often provokes a sense of relief, it can also be a source of apprehension and vulnerability regarding the future.
- Conditions
- Breast Cancer, Emotional Disturbances, Emotional Dysfunction, Anxiety Depression
- Trial name
- NCT03336827
- Testing
- Cognitive-Behavioral Group Therapy and Hypnosis
- Where
- Belgium
- Volunteers
- 120 people
- Sponsor
- Université Libre de Bruxelles
Tuberous Sclerosis Complex
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Tuberous Sclerosis is a rare genetic disorder that affects about one in 15,000 individuals. It is part of the phacomatoses: a germline mutation of the gene Tuberous Sclerosis Complex 1 (TSC1) or TSC2 causes a protein dysfunction…
- Trial name
- NCT04112537
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Montpellier
Rheumatoid Arthritis,Osteoarthritis
A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)
The study is designed to compare the risk of cardiovascular events (heart attacks, strokes) in patients receiving either etoricoxib or diclofenac. It will also compare the gastrointestinal tolerability of the two medicines.
- Trial name
- NCT00250445
- Testing
- MK0663, etoricoxib, Comparator: Diclofenac sodium
- Volunteers
- 23,498 people
- Sponsor
- Organon and Co
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Rutgers University Study of the Genetics of Pulmonary Hypertension
The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligible, and a diagnosis of PH is NOT required.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- RUGCC-PH (NCT07217522)
- Testing
- Saliva sample, Health surveys
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients
Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis
This was a prospective open label randomized control trial, which was conducted for a period of one and half year from January 2014 to June 2015.
- Trial name
- NCT03200002
- Testing
- Cyclophosphamide, Mycophenolate Mofetil
- Volunteers
- 49 people
- Sponsor
- Chitwan Medical College
Arthritis, Rheumatoid
Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the…
- Trial name
- NCT00628095
- Testing
- CE-224,535
- Where
- 27 sites in United States, Chile and 5 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Breast Cancer, Ovarian Cancer
Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer
A phase I trial to determine the recommended phase two dose of the combination of carboplatin and olaparib.
- Conditions
- Breast Cancer, Ovarian Cancer, Advanced Cancer
- Trial name
- REVIVAL (NCT02418624)
- Testing
- carboplatin, olaparib
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- The Netherlands Cancer Institute
Onchocerciasis
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
Onchocerciasis is a major public health problem in affected countries that causes disease-induced disability, and overall loss of economic productivity.
- Trial name
- NCT04913610
- Testing
- ABBV-4083, Albendazole
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 153 people
- Sponsor
- AbbVie
Healthy
Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment
To assess the influence of different degrees of renal impairment on safety, tolerability, pharmacodynamics and pharmacokinetics of 1.0 mg of BIBT 986 BS given as a single dose infusion over 30 minutes in comparison to a normal…
- Trial name
- NCT02254070
- Testing
- BIBT 986 BS
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim